LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary
- PMID: 18986509
- PMCID: PMC2607298
- DOI: 10.1186/1741-7015-6-33
LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary
Abstract
Parkinson's disease is the most common neurodegenerative movement disorder and affects about 2% of the population over the age of 60 years. In 2004, mutations in the LRRK2 gene were first described and turned out to be the most frequent genetic cause of familial and sporadic Parkinson's disease and may account for up to 40% of patients in distinct populations. Based on these findings, Latourelle and colleagues show that the penetrance of the most common LRRK2 mutation is higher in patients with familial compared with sporadic Parkinson's disease and identified a substantial number of affected relatives of mutation carriers not presenting with a LRRK2 mutation themselves. This commentary discusses the role of genetic and/or environmental susceptibility factors modulating the expressivity of the disease trait, how these factors may contribute to the phenomenon of phenocopies in genetically defined Parkinson's disease pedigrees, and how the findings of Latourelle and colleagues, published this month in BMC Medicine, relate to current concepts of genetic counselling.
Figures

Comment on
-
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32. BMC Med. 2008. PMID: 18986508 Free PMC article.
Similar articles
-
Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.Parkinsonism Relat Disord. 2013 Oct;19(10):897-900. doi: 10.1016/j.parkreldis.2013.05.003. Epub 2013 May 28. Parkinsonism Relat Disord. 2013. PMID: 23726462
-
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32. BMC Med. 2008. PMID: 18986508 Free PMC article.
-
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.Lancet. 2005 Jan 29-Feb 4;365(9457):410-2. doi: 10.1016/S0140-6736(05)17828-3. Lancet. 2005. PMID: 15680455
-
The curious case of phenocopies in families with genetic Parkinson's disease.Mov Disord. 2011 Aug 15;26(10):1793-802. doi: 10.1002/mds.23853. Epub 2011 Jul 6. Mov Disord. 2011. PMID: 21735483 Review.
-
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.FEBS J. 2009 Nov;276(22):6455-63. doi: 10.1111/j.1742-4658.2009.07344.x. Epub 2009 Oct 5. FEBS J. 2009. PMID: 19804413 Review.
Cited by
-
Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease.ChemMedChem. 2019 Sep 4;14(17):1580-1585. doi: 10.1002/cmdc.201900321. Epub 2019 Aug 22. ChemMedChem. 2019. PMID: 31365783 Free PMC article.
-
A vision of the future for BMC Medicine: serving science, medicine and authors.BMC Med. 2009 Oct 7;7:55. doi: 10.1186/1741-7015-7-55. BMC Med. 2009. PMID: 19811626 Free PMC article.
-
A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease.Front Aging Neurosci. 2019 Jan 30;11:13. doi: 10.3389/fnagi.2019.00013. eCollection 2019. Front Aging Neurosci. 2019. PMID: 30760999 Free PMC article.
-
Regulation of LRRK2 expression points to a functional role in human monocyte maturation.PLoS One. 2011;6(6):e21519. doi: 10.1371/journal.pone.0021519. Epub 2011 Jun 27. PLoS One. 2011. PMID: 21738687 Free PMC article.
-
Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.Biosci Rep. 2020 Oct 30;40(10):BSR20202225. doi: 10.1042/BSR20202225. Biosci Rep. 2020. PMID: 32975566 Free PMC article.
References
-
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607. doi: 10.1016/j.neuron.2004.11.005. - DOI - PubMed
-
- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, Brug M van der, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600. doi: 10.1016/j.neuron.2004.10.023. - DOI - PubMed
-
- Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain. 2005;128:3000–3011. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical